Engineered immune cells take on childhood blood cancers in early trial
NCT ID NCT06173518
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new CAR T-cell therapy called AUTO1 (obe-cel) in up to 30 children with B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The therapy uses the child's own immune cells, which are modified in a lab to recognize and attack cancer cells. The main goals are to check safety and see how many children achieve complete remission within three months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AUTO1 (Obecabtagene autoleucel [Obe-cel]) - a type of CAR T-cell therapy made from the patient's own immune cells
What this could lead to
If successful, this could offer a new treatment option for children with hard-to-treat B-cell cancers that have come back or not responded to standard therapy.
What could go wrong
This is an early-phase trial with only 30 participants, so results may not apply to all patients. CAR T-cell therapy can cause serious side effects like cytokine release syndrome and low antibody levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital of Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact
-
Great North Children's Hospital
RECRUITINGNewcastle upon Tyne, United Kingdom
Contact
-
Great Ormond Street Hospital for Children NHS Foundation Trust
RECRUITINGLondon, United Kingdom
Contact
-
Hospital Nino Jesus
RECRUITINGMadrid, Spain
Contact
-
Hospital Vall d'Hebron
RECRUITINGBarcelona, Spain
Contact
-
Methodist Children's Hospital
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
-
Primary Children's Hospital
RECRUITINGSalt Lake City, Utah, 84113, United States
Contact
-
Royal Manchester Children's Hospital
RECRUITINGManchester, United Kingdom
Contact